Ultragenyx Pharmaceutical Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 127.39 million compared to USD 103.35 million a year ago. Net loss was USD 123.19 million compared to USD 151.83 million a year ago. Basic loss per share from continuing operations was USD 1.52 compared to USD 2.16 a year ago.
For the full year, revenue was USD 434.25 million compared to USD 363.33 million a year ago. Net loss was USD 606.64 million compared to USD 707.42 million a year ago. Basic loss per share from continuing operations was USD 8.25 compared to USD 10.12 a year ago.